- Proteomics International Laboratories (PIQ) signs a binding letter of intent to introduce PromarkerD to the United States
- The contract was signed with Sonic Healthcare USA, regarding entering an exclusive licence for use of the company’s PromarkerD test for diabetic kidney disease in America
- The letter of intent documents the terms and expectations for how Proteomics and Sonic will work together to bring the test to patients in the country
- The companies are aiming to finalise the contract by December 31, subject to conditions
- Proteomics shares climb 12.4 per cent, trading at $1 at 1:16 pm AEST
Proteomics International Laboratories (PIQ) has signed a binding letter of intent to introduce PromarkerD to the United States.
The contract was signed with Sonic Healthcare USA regarding entering an exclusive licence for use of the company’s PromarkerD test for diabetic kidney disease in America.
PromarkerD is a blood test that can predict kidney function decline in type two diabetes and is the only test capable of predicting the onset of the disease in patients with diabetes and no existing diabetic kidney disease.
The early diagnosis of diabetic kidney disease using PromarkerD testing could help inform doctors’ treatment decisions to improve clinical outcomes for patients.
The letter of intent documents the terms and expectations for how Proteomics and Sonic will work together to bring the test to patients in the US.
Proteomics International Managing Director Dr Richard Lipscombe said this was a pivotal point in the global roll-out of PromarkerD.
“It is rewarding for us to see their [Sonic Heathcare] appreciation for what PromarkerD can offer diabetes patients,” Dr Lipscombe said.
“We have been working with Sonic Healthcare USA towards this goal for fifteen months, and now look forward to building upon this foundation and taking our world first predictive test for diabetic kidney disease into not only the US, but also Europe where the test already has regulatory approval.”
The companies are aiming to finalise the contract by December 31, subject to conditions.
Proteomics shares climbed 12.4 per cent, trading at $1 at 1:16 pm AEST.